Minimal Residual Disease Status Predicts Outcome in Patients
With Previously Untreated Follicular Lymphoma: A Prospective
Analysis of the Phase III GALLIUM Study

J 2024

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

POTT, Christiane, Vindi JURINOVIC, Judith TROTMAN, Britta KEHDEN, Michael UNTERHALT et. al.

Základní údaje

Originální název

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

Autoři

POTT, Christiane, Vindi JURINOVIC, Judith TROTMAN, Britta KEHDEN, Michael UNTERHALT, Michael HEROLD, van der Jagt RICHARD, Ann JANSSENS, Michael KNEBA, Jiří MAYER (203 Česká republika, domácí), Moya YOUNG, Christian SCHMIDT, Andrea KNAPP, Tina NIELSEN, Helen BROWN, Nathalie SPIELEWOY, Chris HARBRON, Alessia BOTTOS, Kirsten MUNDT, Robert MARCUS, Wolfgang HIDDEMANN a Eva HOSTER

Vydání

Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 45.300 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1200/JCO.23.00838

UT WoS

001235636300015

Klíčová slova anglicky

Follicular Lymphoma

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 6. 2024 14:37, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. Patients and methods: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. Results: MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. Conclusion: MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.

Citovat

POTT, Christiane, Vindi JURINOVIC, Judith TROTMAN, Britta KEHDEN, Michael UNTERHALT, Michael HEROLD, van der Jagt RICHARD, Ann JANSSENS, Michael KNEBA, Jiří MAYER, Moya YOUNG, Christian SCHMIDT, Andrea KNAPP, Tina NIELSEN, Helen BROWN, Nathalie SPIELEWOY, Chris HARBRON, Alessia BOTTOS, Kirsten MUNDT, Robert MARCUS, Wolfgang HIDDEMANN a Eva HOSTER. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. Journal of clinical oncology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024, roč. 42, č. 5, s. 1-13. ISSN 0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.00838.

@article{2409573,
   author = {Pott, Christiane and Jurinovic, Vindi and Trotman, Judith and Kehden, Britta and Unterhalt, Michael and Herold, Michael and Richard, van der Jagt and Janssens, Ann and Kneba, Michael and Mayer, Jiří and Young, Moya and Schmidt, Christian and Knapp, Andrea and Nielsen, Tina and Brown, Helen and Spielewoy, Nathalie and Harbron, Chris and Bottos, Alessia and Mundt, Kirsten and Marcus, Robert and Hiddemann, Wolfgang and Hoster, Eva},
   article_location = {PHILADELPHIA},
   article_number = {5},
   doi = {http://dx.doi.org/10.1200/JCO.23.00838},
   keywords = {Follicular Lymphoma},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of clinical oncology},
   title = {Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study},
   url = {https://ascopubs.org/doi/10.1200/JCO.23.00838},
   volume = {42},
   year = {2024}
}

TY  - JOUR
ID  - 2409573
AU  - Pott, Christiane - Jurinovic, Vindi - Trotman, Judith - Kehden, Britta - Unterhalt, Michael - Herold, Michael - Richard, van der Jagt - Janssens, Ann - Kneba, Michael - Mayer, Jiří - Young, Moya - Schmidt, Christian - Knapp, Andrea - Nielsen, Tina - Brown, Helen - Spielewoy, Nathalie - Harbron, Chris - Bottos, Alessia - Mundt, Kirsten - Marcus, Robert - Hiddemann, Wolfgang - Hoster, Eva
PY  - 2024
TI  - Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
JF  - Journal of clinical oncology
VL  - 42
IS  - 5
SP  - 1-13
EP  - 1-13
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 0732183X
KW  - Follicular Lymphoma
UR  - https://ascopubs.org/doi/10.1200/JCO.23.00838
N2  - Purpose: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. Patients and methods: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. Results: MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. Conclusion: MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.
ER  -

POTT, Christiane, Vindi JURINOVIC, Judith TROTMAN, Britta KEHDEN, Michael UNTERHALT, Michael HEROLD, van der Jagt RICHARD, Ann JANSSENS, Michael KNEBA, Jiří MAYER, Moya YOUNG, Christian SCHMIDT, Andrea KNAPP, Tina NIELSEN, Helen BROWN, Nathalie SPIELEWOY, Chris HARBRON, Alessia BOTTOS, Kirsten MUNDT, Robert MARCUS, Wolfgang HIDDEMANN a Eva HOSTER. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. \textit{Journal of clinical oncology}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2024, roč.~42, č.~5, s.~1-13. ISSN~0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.23.00838.

Podrobný výpis o publikaci